SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cadila Healthcare trades in green on the bourses

22 Jan 2019 Evaluate

Cadila Healthcare is currently trading at Rs. 345.75, up by 1.05 points or 0.30% from its previous closing of Rs. 344.70 on the BSE.

The scrip opened at Rs. 344.35 and has touched a high and low of Rs. 346.45 and Rs. 344.35 respectively. So far 3820 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 445.00 on 22-Jan-2018 and a 52 week low of Rs. 330.65 on 26-Oct-2018.

Last one week high and low of the scrip stood at Rs. 359.50 and Rs. 343.00 respectively. The current market cap of the company is Rs. 35288.41 crore.

The promoters holding in the company stood at 74.79%, while Institutions and Non-Institutions held 17.33% and 7.88% respectively.

Zydus Cadila has received the tentative approval from the United States Food and Drug Administration (USFDA) to market Esomeprazole Magnesium Delayed-Release Capsules (US RLD - NEXIUM). It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.

Esomeprazole belongs to the group of medicines termed as proton pump inhibitors. Esomeprazole reduces the amount of acid secreted by the stomach. The drug is used to treat the symptoms of gastroesophageal reflux disease, to reduce the risk of stomach ulcers in some people taking pain medicines, treat patients with stomach infection (Helicobacter pylori) along with certain antibiotics and long-term treatment of conditions where stomach makes too much acid.

The group now has 247 approvals and has so far filed over 330 ANDAs since the commencement ofthe filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

948.10 5.55 (0.59%)
20-Apr-2026 09:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1677.45
Dr. Reddys Lab 1234.80
Cipla 1241.25
Zydus Lifesciences 948.10
Lupin 2332.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×